CDK4 and neoplasm: Most MPM patients could respond to CDK4/6i, which may not only arrest tumour growth but also help to convert the mesotheliomas that are rarely immunologically ‘cold’ but more frequently in intermediate inflammatory states [133], into ‘hot’ tumours responsive to immunotherapy.